ProCE Banner Activity

CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer

Slideset Download
Conference Coverage
Phase III study of adjuvant capecitabine in patients with HER2-negative breast cancer and pathologic residual disease following standard anthracycline/taxane neoadjuvant chemotherapy.

Released: December 15, 2015

Expiration: December 13, 2016

No longer available for credit.

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech BioOncology

Novartis Pharmaceuticals Corporation